Regeneron Pharmaceuticals, Inc. (REGN)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN). Investors who purchased Regeneron securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Regeneron has violated federal securities laws.
On June 27, 2023, Regeneron received a response letter from the FDA which declined its application for an 8mg dose of aflibercept, marketed in the U.S. as Eylea. The company stated that the denial was due to an ongoing review of third-party filer findings. Following this news, Regeneron stock dropped 8.7% on June 27, 2023.
If you are aware of any facts relating to this investigation or purchased Regeneron shares, you can assist this investigation. You can also contact Peretz Bronstein or his law clerk and client relations manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Why Bronstein, Gewirtz & Grossman:
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Attorney advertising. Prior results do not guarantee similar outcomes.